MELanoma Brain Metastasis Treated With CYberknife
Key facts
- Where
- Milan, ItalySee the site
Where in Italy
- European Institute of Oncology, MilanMilan, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- European Institute of Oncology
- Trial code
- NCT07691255
- Record updated
- 10 September 2026
- Original description
Melanoma is a type of cancer that can spread to the brain, making the disease harder to treat and worsening both survival and quality of life.Read full original descriptionShow less
Impact of Stereotactic Radiosurgery With Cyberknife In Patients With Brain Melanoma Metastases In The Era Of New Drugs
Melanoma is a type of cancer that can spread to the brain, making the disease harder to treat and worsening both survival and quality of life.
In recent years, treatments have improved significantly thanks to advances in surgery, radiotherapy, immunotherapy, and targeted therapy. These new treatments have greatly increased survival rates for patients with metastatic melanoma.
This study focuses on stereotactic radiosurgery, a highly precise form of radiotherapy used to treat brain metastases. Researchers want to better understand how this treatment works when combined with immunotherapy or targeted therapy, and whether the timing and sequence of treatments can improve outcomes.
Between 2026 and 2028, patients treated at the IEO for melanoma brain metastases will be observed and their clinical data collected. The goal is to improve future treatment strategies and help doctors choose the best therapeutic approach for each patient.
Inclusion: Age > 18; Written informed consent for treatment and research purposes; Melanoma Brain Metastases (MBM) diagnosed with brain MRI/CT; MBM treatable with stereotactic radiotherapy; Systemic therapy (immunotherapy, target therapy, or both) is allowed, as concurrent or non-concurrent treatment with stereotactic radiotherapy.
Exclusion: Previous whole-brain radiotherapy or surgical removal of brain metastases; Leptomeningeal neoplastic infiltration; Patients with histological diagnosis of non-cutaneous melanoma (e.g. uveal melanoma).